Navigation Links
Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
Date:7/2/2012

CRANBURY, N.J., July 2, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that it has entered into a definitive securities agreement and priced a private placement of 3,873,000 shares of its common stock, Series A warrants to purchase 31,988,151 shares of its common stock, and Series B warrants to purchase 35,488,380 shares of its common stock.  Funds under the management of QVT Financial LP have agreed to pay $0.50 for each share of common stock and $0.49 for each Series A warrant and each Series B warrant, resulting in gross proceeds to Palatin of $35,000,000, with net proceeds, after deducting estimated offering expenses, of approximately $34,500,000.

The private placement is expected to close on or about July 5, 2012, subject to customary closing conditions.

Palatin intends to use the proceeds from this offering for general corporate purposes and working capital, including its clinical trial program with bremelanotide for female sexual dysfunction, preclinical and clinical development of its melanocortin receptor-1 peptide program, preclinical and clinical development of its PL-3994 program and preclinical and clinical development of other portfolio products.

Both Series A and Series B warrants are exercisable at an initial exercise price of $0.01 per share.  The Series A warrants are exercisable immediately upon issuance and expire on the tenth anniversary of the date of issuance.  The Series B warrants are also exercisable immediately upon issuance, but only if Palatin's stockholders increase the number of its authorized shares of common stock, and expire on the tenth anniversary of the date of the increase in the number of authorized shares.  Both the Series A warrants and the Series B warrants are subject to limitation on exercise if the holder and its affiliates would beneficially own more than 9.99% of the total number of Palatin's shares of common stock following such exercise.
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
9. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
10. Animal Biotechnology - Technologies, Markets and Companies
11. Gene Therapy - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... German . Photographers ... you can see which branch a bird is sitting on, ... the telephoto lens for high-magnification images requires considerable skill. It ... study proteins, the active biomolecules of cells. , Olga Schubert, ... Biology, and her colleagues have now come up with a ...
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine ... achieved 50% enrollment of the total projected enrollment ... the safety and preliminary efficacy of the medical ... for Knee Osteoarthritis (KOA). To date the trial ... The Phase I open label clinical ...
(Date:5/17/2013)... The paradigm of ‘one drug, one ... can help predict the adverse and therapeutic effects of ... of Computational Biology at the Genomics Laboratory, Covance, will ... high-quality genomics when used as part of the QC ... data sets to identify key clinical targets even in ...
(Date:5/16/2013)... 2013 The Stirling Ultracold Model ... Inc., Athens, OH, USA, won the Outstanding New Product ... Society for Biological and Environmental Repositories (ISBER) at their ... one product annually, recognizes the company’s development and introduction ... The award was presented to Global Cooling’s CEO ...
Breaking Biology Technology:Proteome atlas for the tuberculosis pathogen 2Proteome atlas for the tuberculosis pathogen 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2
... Sharer, chairman and chief executive officer of Amgen (NASDAQ: ... retire from the Company at the end of 2012, following ... transition process, Sharer will step down as CEO effective May ... of Directors until December 31, 2012, at which time he ...
... 2011   Ecology Coatings, Inc. (OTCQB: ECOC), a ... that it has developed bio-based GRAS (generally recognized as ... GRAS, they can be used to make coatings that ... in direct contact with food and food packaging. ...
... ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) ... to commercialize hepatocytes derived from human iPS (induced ... the National Institute of Biomedical Innovation (NIBIO; Director ... effective in-vitro drug screening for hepatic toxicity and ...
Cached Biology Technology:Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 2Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 3Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products 2ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes - Expected Launch in Q2 2012 2
(Date:5/15/2013)... its benefit in moderating gout risk, new research reveals ... reduce uric acid (urate) levels to a clinically significant ... alone or in combination with allopurinol, appears to have ... gout patients according to the results published in the ... Rheumatism . , Gout is an inflammatory arthritis ...
(Date:5/15/2013)... trial to date to examine the efficacy of PARP ... than breast and ovarian cancer, the oral drug olaparib ... prostate cancers. Results of the study, led by researchers ... of Pennsylvania and Sheba Medical Center in Tel Hashomer, ... Clinical Oncology,s annual meeting in Chicago in early June ...
(Date:5/15/2013)... from the middle Devonian era some 380 million ... of the capacity of ecosystems to remain stable in ... today (May 15) in the online journal PLOS ... the head counts of specimens paleontologists test the ... factors such as predation and organism body size from ...
Breaking Biology News(10 mins):Vitamin C does not lower uric acid levels in gout patients 2PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2Clam fossils divulge secrets of ecologic stability 2
... to improve cancer treatments have created a tiny drug transporter ... the equivalent of an expressway into a target cell. ... a piece of RNA. Lipids are fatty molecules that help ... segment encased in the carrier sets off a process to ...
... in Seattle have worked to solve the mystery of why ... they return from the ocean to mate and spawn. In ... the team use models to estimate the potential impact ... decades ahead. Stricken coho salmon ( Oncorhynchus kisutch ) ...
... astounding evolutionary event occurred: certain bacteria became obliged to ... events that resulted in what is now the mitochondria, ... recent study by researchers at the University of Hawaii ... provides strong evidence that mitochondria share a common evolutionary ...
Cached Biology News:Scientists design nano-sized drug transporter to fight disease 2Scientists design nano-sized drug transporter to fight disease 3Models show Coho salmon at risk in US urbanizing watersheds 2Mitochondria share an ancestor with SAR11, a globally significant marine microbe 2
Request Info...
... containing a clone of the human Topoisomerase II ... alters the topological state of nucleic acids by ... break which generates a separate DNA helix (1,2) ... passage mechanism, the enzyme can relax negatively or ...
Request Info...
... The Neural Stem Cell Expansion Kit - ... vitro neural stem cell expansion as neurospheres ... a specially formulated N-2 Plus Media Supplement, which ... (Johe, K.K. et al . (1996) Genes ...
Biology Products: